STOCK TITAN

Atossa Therapeutics Inc - ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Atossa Therapeutics Inc (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company pioneering novel therapies for breast cancer and breast health conditions. This page provides investors and healthcare stakeholders with comprehensive access to official press releases, clinical trial developments, and regulatory updates directly from the company.

Track progress on key initiatives including (Z)-endoxifen clinical trials, innovative drug delivery systems like intraductal microcatheter technology, and strategic partnerships. Our curated news collection ensures timely updates on FDA communications, research milestones, and intellectual property developments relevant to oncology therapeutics.

Discover updates across three primary categories: clinical research advancements in estrogen receptor-targeted treatments, regulatory filings for breast cancer therapies, and scientific collaborations enhancing drug delivery platforms. Each update is sourced from verified company communications to maintain accuracy and compliance.

Bookmark this page for streamlined access to Atossa's latest developments in selective estrogen receptor modulation and precision medicine. Regularly updated to serve as your primary resource for understanding the company's progress in addressing unmet needs in oncology care.

Rhea-AI Summary
Atossa Therapeutics (ATOS) announces positive safety and efficacy data from Phase 2 EVANGELINE trial for ER+/HER2- breast cancer treatment. The study shows significant reduction in Ki-67 levels, target lesion decreases, and promising clinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported fully enrolling two Phase 2 studies with data expected in the second half of 2024. They also dosed the first patient in a new Phase 2 breast cancer prevention study and provided updates on ongoing trials. The company ended 2023 with $88.5 million in cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) announces successful 5-year treatment of pre-menopausal ER+ breast cancer patient with (Z)-endoxifen therapy. The patient remains cancer-free with no safety issues. (Z)-endoxifen shows promise in changing breast cancer treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.16%
Tags
none
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) has regained compliance with Nasdaq's minimum closing bid price requirement, ensuring its listing on the stock exchange. The company focuses on developing innovative medicines for breast cancer using (Z)-endoxifen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Atossa Therapeutics, Inc. appoints Dr. Tessa Cigler to its board of directors, enhancing its expertise in breast cancer treatment. Dr. Cigler's background in medical oncology and clinical investigation brings valuable insights to Atossa's (Z)-endoxifen development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
management
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) announced the presentation of data from the 40mg PK run-in cohort of the Phase 2 EVANGELINE study at the AACR Annual Meeting. The study focuses on (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer, aiming to improve treatment options. Dr. Steven Quay, Atossa’s CEO, expressed excitement about the potential impact of (Z)-endoxifen in transforming premenopausal women's cancer treatment. The presentation details were provided for the upcoming event in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.75%
Tags
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) doses first patient with SERM in RECAST DCIS study, a Phase 2 platform study for breast cancer treatment without surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has fully enrolled the (Z)-endoxifen arm of the Phase 2 I-SPY 2 clinical trial, evaluating it as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive invasive breast cancer. The study aims to down-stage the tumor, improve tumor resectability, and reduce breast cancer recurrence. The company looks forward to seeing data from this study in the second half of 2024. The (Z)-endoxifen arm enrolled 20 patients as part of the I-SPY 2 Endocrine Optimization Pilot Protocol (EOP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: ATOS), announces significant progress in 2023, with four Phase 2 trials investigating proprietary (Z)-endoxifen and important research with Weill Cornell Medicine. The Phase 2 Karisma-Endoxifen trial reached full enrollment in November 2023, studying the effect of (Z)-endoxifen in premenopausal women with measurable breast density.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
Rhea-AI Summary
Dr. Steven Quay, MD, PhD discusses cost-benefit analysis, mRNA vaccines, and SARS-CoV-2 origins in a one-hour podcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
covid-19
Atossa Therapeutics Inc

Nasdaq:ATOS

ATOS Rankings

ATOS Stock Data

80.49M
129.09M
0.06%
28.55%
7.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE